Effect of glucocorticoids on mortality in patients with acute respiratory distress syndrome: A meta‑analysis

Zhao,Qing; Shi,Jia‑Xin; Hu,Rong; Li,Qin; Zhang,Chen‑Ying; Li,Jia‑Shu

doi:10.3892/etm.2019.8156

Effect of glucocorticoids on mortality in patients with acute respiratory distress syndrome: A meta‑analysis

Authors:
- Qing Zhao
- Jia‑Xin Shi
- Rong Hu
- Qin Li
- Chen‑Ying Zhang
- Jia‑Shu Li
View Affiliations

Affiliations: Outpatient Department, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu 222002, P.R. China, Department of Pulmonary and Critical Care Medicine, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu 222002, P.R. China
Published online on: October 31, 2019 https://doi.org/10.3892/etm.2019.8156
Pages: 4913-4920

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To date, the efficacy of glucocorticoid therapy to reduce mortality in patients with acute respiratory distress syndrome (ARDS) has remained controversial among the studies available. The present meta‑analysis study aimed to further clarify the impact of glucocorticoid therapy on mortality in patients with ARDS by performing a pooled analysis of the previous data. The PubMed, Chinese Knowledge Infrastructure, Wanfang and Cochrane trials databases were searched for relevant studies published between 1966 and 2016. Randomized controlled trials (RCTs) that included the use of glucocorticoids in patients with ARDS and had reported on mortality were included. Odds ratios (OR) and 95% confidence intervals (CI) for mortality were calculated. A total of 10 RCTs were included in the meta‑analysis. Of these, 4 studies used high‑dose glucocorticoid therapy, while 6 used low‑dose glucocorticoid therapy. In the pooled analysis, glucocorticoids were indicated to significantly reduce ARDS‑associated mortality (OR=0.64, 95% CI: 0.48‑0.85, P=0.002). Further subgroup analysis indicated the following: i) Long‑term low‑dose glucocorticoid therapy reduced ARDS‑associated mortality compared with that in the control group (OR=0.60, 95% CI: 0.44‑0.82, P=0.001), whereas high‑dose short‑term glucocorticoid therapy did not reduce mortality (OR=0.82, 95% CI: 0.43‑1.57, P=0.55). ii) Early initiation of glucocorticoid therapy was associated with reduced mortality compared with that in the control group (OR=0.60, 95% CI: 0.44‑0.83, P=0.002); however, late initiation did not reduce mortality (OR=0.36, 95% CI: 0.03‑3.76, P=0.39). iii) Therapeutic rather than preventive use of glucocorticoids reduced mortality (OR=0.65, 95% CI: 0.49‑0.86, P=0.003). Overall, the present meta‑analysis suggests that early initiation of long‑term low‑dose glucocorticoid therapy reduces mortality of patients with ARDS.

View Figures

View References

1	Leaver SK and Evans TW: Acute respiratory distress syndrome. BMJ. 335:389–394. 2007. View Article : Google Scholar : PubMed/NCBI
2	Acute Respiratory Distress Syndrome Network, ; Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT and Wheeler A: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 342:1301–1308. 2000. View Article : Google Scholar : PubMed/NCBI
3	Boyle AJ, Mac Sweeney R and McAuley DF: Pharmacological treatments in ARDS; a state-of-the-art update. BMC Med. 11:1662013. View Article : Google Scholar : PubMed/NCBI
4	Weigelt JA, Norcross JF, Borman KR and Snyder WH III: Early steroid therapy for respiratory failure. Arch Surg. 120:536–540. 1985. View Article : Google Scholar : PubMed/NCBI
5	Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA and Murray JF: Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis. 138:62–68. 1988. View Article : Google Scholar : PubMed/NCBI
6	Steinberg KP, Hudson LD, Goodman RB, Hough CL, Lanken PN, Hyzy R, Thompson BT and Ancukiewicz M; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, : Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. The New England journal of medicine. 354:1671–1684. 2006. View Article : Google Scholar : PubMed/NCBI
7	Meduri GU, Golden E, Freire AX, Taylor E, Zaman M, Carson SJ, Gibson M and Umberger R: Methylprednisolone infusion in early severe ARDS: Results of a randomized controlled trial. Chest. 131:954–963. 2007. View Article : Google Scholar : PubMed/NCBI
8	Peter JV, John P, Graham PL, Moran JL, George IA and Bersten A: Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis. BMJ. 336:1006–1009. 2008. View Article : Google Scholar : PubMed/NCBI
9	Higgins JP, Thompson SG, Deeks JJ and Altman DG: Measuring inconsistency in meta-analyses. BMJ. 327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
10	Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ and Metz CA: Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. Chest. 92:1032–1036. 1987. View Article : Google Scholar : PubMed/NCBI
11	Bernard GR, Luce JM, Sprung CL, Rinaldo JE, Tate RM, Sibbald WJ, Kariman K, Higgins S, Bradley R, Metz CA, et al: High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med. 317:1565–1570. 1987. View Article : Google Scholar : PubMed/NCBI
12	Meduri GU, Headley AS, Golden E, Carson SJ, Umberger RA, Kelso T and Tolley EA: Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: A randomized controlled trial. JAMA. 280:159–165. 1998. View Article : Google Scholar : PubMed/NCBI
13	Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, Della Porta R, Giorgio C, Blasi F, Umberger R and Meduri GU: Hydrocortisone infusion for severe community- acquired pneumonia: A preliminary randomized study. Am J Respir Crit Care Med. 171:242–248. 2005. View Article : Google Scholar : PubMed/NCBI
14	Annane D, Sébille V and Bellissant E; Ger-Inf-05 Study Group, : Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit Care Med. 34:22–30. 2006. View Article : Google Scholar : PubMed/NCBI
15	Seam N, Meduri GU, Wang H, Nylen ES, Sun J, Schultz MJ, Tropea M and Suffredini AF: Effects of methylprednisolone infusion on markers of inflammation, coagulation, and angiogenesis in early acute respiratory distress syndrome. Crit Care Med. 40:495–501. 2012. View Article : Google Scholar : PubMed/NCBI
16	Tongyoo S, Permpikul C, Mongkolpun W, Vattanavanit V, Udompanturak S, Kocak M and Meduri GU: Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: Results of a randomized controlled trial. Crit Care. 20:3292016. View Article : Google Scholar : PubMed/NCBI
17	ARDS Definition Task Force, ; Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L and Slutsky AS: Acute respiratory distress syndrome: The Berlin definition. JAMA. 307:2526–2533. 2012.PubMed/NCBI
18	Vincent JL, Akça S, De Mendonça A, Haji-Michael P, Sprung C, Moreno R, Antonelli M and Suter PM; SOFA Working Group. Sequntial organ failure assessment, : The epidemiology of acute respiratory failure in critically ill patients(*). Chest. 121:1602–1609. 2002. View Article : Google Scholar : PubMed/NCBI
19	Meduri GU, Bridges L, Shih MC, Marik PE, Siemieniuk RAC and Kocak M: Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: Analysis of individual patients' data from four randomized trials and trial-level meta-analysis of the updated literature. Intensive Care Med. 42:829–840. 2016. View Article : Google Scholar : PubMed/NCBI
20	Meduri GU, Muthiah MP, Carratu P, Eltorky M and Chrousos GP: Nuclear factor-kappaB- and glucocorticoid receptor alpha- mediated mechanisms in the regulation of systemic and pulmonary inflammation during sepsis and acute respiratory distress syndrome. Evidence for inflammation-induced target tissue resistance to glucocorticoids. Neuroimmunomodulation. 12:321–338. 2005. View Article : Google Scholar : PubMed/NCBI
21	Annane D, Pastores SM, Rochwerg B, Arlt W, Balk RA, Beishuizen A, Briegel J, Carcillo J, Christ-Crain M, Cooper MS, et al: Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically Ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Crit Care Med. 45:2078–2088. 2017. View Article : Google Scholar : PubMed/NCBI
22	Snijders D, Daniels JM, de Graaff CS, van der Werf TS and Boersma WG: Efficacy of corticosteroids incommunity-acquired pneumonia: A randomized double-blinded clinical trial. Am J Respir Crit Care Med. 181:975–982. 2010. View Article : Google Scholar : PubMed/NCBI
23	Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB and Matthay MA; NHLBI ARDS Network, : Subphenotypes in acute respiratory distress syndrome: Latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2:611–620. 2014. View Article : Google Scholar : PubMed/NCBI